sur Berlin Heals Holding AG
Berlin Heals Launches C-MIC IV Heart Failure Trial
Berlin Heals Holding AG has initiated the C-MIC IV trial, an important step for its microcurrent therapy aimed at heart failure. Based in Zug, Switzerland, the company is conducting this international, randomized, double-blind, sham-controlled study to further assess the therapy's efficacy and safety. The trial follows the C-MIC III study's less invasive approach and will include 60 patients across six European countries.
The trial targets patients with symptomatic heart failure of either ischemic or non-ischemic origin, having a reduced ejection fraction above 20%. A novel aspect of this study is that all patients will have devices implanted, but will not know whether the therapy is active. The first patient was treated in Serbia, highlighting the trial's international scope.
John Brumfield, CEO, emphasized the trial's significance in building evidence for this innovative therapy. This effort aims to enhance the clinical understanding of microcurrent technology for heart failure.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Berlin Heals Holding AG